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Introduction

Discussion

Conclusion

Spiradenocarcinoma is a malignancy of eccrine origin, with only 120
reported cases in the literature.1 Elderly males and females are equally
affected.2 Benign spiradenomas along with their malignant counterpart are
more frequent in patients with Brooke-Spiegler syndrome or familial
eccrine spiradenoma, owing to the increased incidence of
folliculosebaceous-apocrine tumors seen with these entities.3

Spiradenocarcinoma commonly develops within an existing spiradenoma.4 Mutations in
the CYLD tumor suppressor gene are known to play a role in hereditary cases, but the
pathogenesis of de novo tumor development is poorly understood. This malignancy
primarily affects the head, trunk, and extremities.5 Tenderness, ulceration, or rapid
evolution herald malignant transformation and mandate further investigation.4

Eccrine spiradenocarcinoma is a rare sweat duct malignancy that may
arise via malignant degeneration of a benign tumor or de novo formation.
Increased incidence in patients with Brooke-Spiegler syndrome or familial
eccrine spiradenoma requires consideration of this tumor in the
appropriate patient base. It is particularly important to identify this
neoplasm early, as spiradenocarcinoma carries a 10-15% mortality rate.8

Case
A 54-year-old female presented for evaluation of a tender, pink-toviolaceous nodule within her right eyebrow (Figure 1). Shave biopsy of the
lesion was performed, which was histologically consistent with
spiradenocarcinoma arising within a spiradenoma (Figures 2, 3).

Histopathology reveals abrupt transition from benign biphasic to malignant monomorphic
cells with nuclear pleomorphism and dilated ductal and vascular structures.4 Higher rates
of recurrence, metastases, and mortality are associated with a high-grade pattern
denoted by stark histologic transition from benign to carcinomatous tumor.6 Overall,
spiradenocarcinomas metastasize at a rate as high as 40%, with preferential spread to
regional lymph nodes, lung, and bone.7
Once diagnosed, thorough imaging via computer tomography (CT), magnetic resonance
imaging (MRI), positron emission tomography (PET), or a combination thereof is
recommended.1 While first line treatment has historically been wide local excision with
margins >2 cm, recent literature has endorsed Mohs micrographic surgery (MMS) as a
viable, and potentially superior, alternative.7 Local recurrence rates range from 17-57%.1,5
For unresectable or metastatic disease, multiple chemotherapy and radiation regimens
have been utilized with variable success, but no formal recommendation yet exists.7
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Figure 1: Pink-toviolaceous nodule within
right eyebrow
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Figure 3: Monophasic, hyperchromatic
cells with mitotic figures, dilated
vascular and ductal structures, and
occasional necrosis (inset).

The malignant lesion was excised and the patient was cancer free at her
recent 9-month follow-up. With these findings, and subsequent
identification
of
additional
spiradenomas,
cylindromas,
and
trichoepitheliomas, the patient was clinically diagnosed with BrookeSpiegler syndrome and referred to a geneticist for further evaluation and
counseling.

Following diagnosis and extirpation of spiradenocarcinoma via surgical or
chemotherapeutic methods, frequent follow-up is recommended. No
specific guidelines exist, but it is reasonable to assess these patients
equivalently to those with previous melanoma diagnoses. Incorporation of
follow-up imaging should also be strongly considered.
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Figure 2: Abrupt transition of benign
biphasic cells to compact,
monomorphic malignant cells.
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